Evidence map›Paper›PMID 41883579›Full record

ArticleiScience2026

Low-dose of yeast beta-glucan on respiratory symptoms and psychological well-being in moderately stressed adults.

Nur Nadia Mohamad Habibullah, Munirah Ismail, Norhayati Ibrahim, Shirley Gee Hoon Tang, Hanif Farhan Mohd Rasdi, Mohamed Faisal Abdul Hamid, Kalavathy Ramasamy, So Fie Tan, Suzana Shahar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nur Nadia Mohamad HabibullahDietetics Programme, Centre for Healthy Ageing and Wellness, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.
Munirah IsmailDietetics Programme, Centre for Healthy Ageing and Wellness, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.
Norhayati IbrahimClinical Psychology Programme, Centre for Healthy Ageing and Wellness (H-CARE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.
Shirley Gee Hoon TangBiomedical Science Programme, Centre for Toxicology and Health Risk Studies (CORE), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.
Hanif Farhan Mohd RasdiOccupational Therapy Programme, Centre for Rehabilitation and Special Needs Studies (ICaRehab), Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.
Mohamed Faisal Abdul HamidRespiratory Unit, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM), Cheras, Kuala Lumpur 56000, Malaysia.
Kalavathy RamasamyCollaborative Drug Discovery Research (CDDR) Group, Faculty of Pharmacy, Universiti Teknologi MARA (UiTM) Cawangan Selangor, Kampus Puncak Alam, Bandar Puncak Alam, Puncak Alam, Selangor Darul Ehsan 42300, Malaysia.
So Fie TanRB (Health) Malaysia Sdn Bhd, Menara 1 Sentrum, Jalan Sambathan, Kuala Lumpur 50470, Malaysia.
Suzana ShaharDietetics Programme, Centre for Healthy Ageing and Wellness, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Yeast beta-glucan (YBG) is an immunomodulatory polysaccharide that enhances host defense, but optimal dosing for respiratory and psychological benefits requires investigation. This 12-week randomized, double-blind, placebo-controlled trial (ISRCTN 48336189) enrolled 198 moderately stressed adults (PSS-10 scores: 14-26) assigned to placebo, low-dose YBG (120 mg), or moderate-dose YBG (204 mg) daily. The primary outcome was upper respiratory tract infection symptom severity measured by WURSS-21. Both YBG doses improved symptoms compared with placebo (adjusted mean change, 95% CI: placebo +3.42 [0.91 to 5.93]; 120 mg -2.27 [-4.82 to 0.28]; 204 mg -3.51 [-6.06 to -0.96]), with only 204 mg exceeding the minimal clinically important difference. Both doses reduced negative mood states (

Indexed as

Health sciencesMedicinePsychiatryPsychology

Identifiers

PMID41883579
PMCPMC13010125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.